Substituted phenolic hydroxy phenyl pyrrolopyrimidine compound, and preparation method therefor and use thereof

By designing substituted phenol-hydroxyphenylpyrrolopyrimidine compounds, the problems of weak activity and poor selectivity of existing inhibitors against USP51 were solved, achieving efficient and safe USP51 inhibition and broadening the horizons of anti-tumor drug development.

WO2024239668A1PCT designated stage expired Publication Date: 2024-11-28NANKAI UNIV

Patent Information

Application Number
PCT/CN2024/071285
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-01-09
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing deubiquitinase inhibitors have weak inhibitory activity against USP51, poor selectivity, and poor selectivity against other deubiquitinases, making it difficult to develop efficient and safe USP51 inhibitors.

Method used

The company designed and synthesized substituted phenolic hydroxyphenyl pyrrolopyrimidine compounds, which, through compounds with specific structural formulas, can efficiently and selectively inhibit deubiquitinase USP51 and be applied to the preparation of anticancer drugs.

Benefits of technology

Compound 5 exhibits highly efficient inhibition of USP51 activity, with high selectivity and safety, and high bioavailability, providing a new approach for anti-tumor drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024071285_28112024_PF_FP_ABST
    Figure CN2024071285_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of chemical medicine, and in particular relates to a substituted phenolic hydroxy phenyl pyrrolopyrimidine compound, and a preparation method therefor and the use thereof. The substituted phenolic hydroxy phenyl pyrrolopyrimidine compound is as shown in formula (I). The preparation process of the present invention is simple and feasible, the prepared quinazoline compound or the pharmaceutically acceptable salt thereof has the effect of effectively inhibiting deubiquitinase USP51, has relatively high selectivity, good safety, high solubility and high bioavailability, and provides a new visual field and thought for broadening the cognitive recognition of USP family, the related mechanism research of deubiquitinase USP51 participating in the protein deubiquitination process, and the development of new anti-tumor small molecule drugs.
Need to check novelty before this filing date? Find Prior Art

Description

A substituted phenolic hydroxyphenyl pyrrolopyrimidine compound and its preparation method and application Technical Field

[0001] The present invention belongs to the technical field of chemical medicines, and in particular relates to a substituted phenolic hydroxyphenyl pyrrolopyrimidine compound, a preparation method and an application thereof. Background Art

[0002] Malignant tumors are among the major diseases that threaten human life. Currently, the main treatments for malignant tumors include surgery, radiotherapy, and chemotherapy. Traditional anti-tumor drugs, however, are hampered by significant toxic side effects and other drawbacks, hindering their further clinical application. Numerous studies have demonstrated that deubiquitinating enzymes (DUBs) play crucial physiological roles by regulating protein interactions, localization, and enzyme activity, thereby influencing cellular processes including transcription, DNA damage signaling and repair, cell cycle progression, oxidative stress, and apoptosis. Their close relationship with tumor development and progression has led to the discovery that DUB inhibitors exhibit significant anti-tumor effects in preclinical studies of various tumor types, making them a hot topic in the research and development of novel anti-tumor drugs.

[0003] Epithelial-mesenchymal transition (EMT) and its reversal process and mesenchymal-epithelial transition (MET) play a key role in tumor metastasis. During the EMT process, epithelial cells lose the adhesion junctions and tight junctions that maintain close contact with neighboring cells. Activation of EMT by multiple transcription factors can induce the migration, invasion and metastasis of tumor cells. ZEB1, as a transcription factor that controls EMT induction, can promote tumor invasion, metastasis and treatment resistance. In many types of cancer, abnormal expression of ZEB1 is associated with invasive behavior, high tumor index, drug resistance, high metabolic plasticity and metastasis. For example, in breast cancer patients, high expression of ZEB1 was found in tumor cells of triple-negative / basal-like breast cancer.

[0004] USP51 is a deubiquitinase that deubiquitinates ZEB1 (Zinc Finger E-Box Binding Homeobox 1). Targeting USP51 may serve as an alternative approach to targeting the oncogenic transcription factor ZEB1. Screening a human deubiquitinase library revealed that USP51 is a ubiquitinase that binds, deubiquitinates, and stabilizes ZEB1. Loss of USP51 in mesenchymal breast cancer cells leads to downregulation of ZEB1 protein and mesenchymal markers, upregulation of E-cadherin-E, and inhibition of cell invasion. Conversely, overexpression of USP51 in epithelial cells leads to upregulation of ZEB1 and mesenchymal cell markers. Furthermore, USP51 can regulate the expression of ZEB1 target genes. Importantly, USP51 is overexpressed in breast cancer patients and correlates with poor survival.

[0005] Currently, the development of USP family inhibitors primarily targets popular targets such as USP7, USP1, and USP9. However, as a relatively novel deubiquitinase, USP51 itself and its inhibitors are relatively unremarkable. Furthermore, the development of selective deubiquitinase inhibitors currently underway still faces numerous challenges: ① Research on deubiquitinases has focused on USP family members, particularly USP7, but most reported inhibitors exhibit weak inhibitory activity, contain undesirable chemical features, or exhibit poor selectivity against currently known deubiquitinases. ② Currently, our understanding of the protein structure and functional substrates of deubiquitinases is inadequate and uneven, and the underlying mechanisms linking deubiquitinases to tumorigenesis remain largely unexplored. Consequently, most current small-molecule inhibitors of deubiquitinases suffer from limitations such as poor specificity. Furthermore, existing inhibitor screening methods and techniques suffer from poor compatibility with real physiological environments and a high risk of false positives. Therefore, the research, design, and synthesis of novel, structurally sound, highly selective, and safe small-molecule inhibitors targeting USP51 are of great scientific significance.

[0006] Summary of the Invention

[0007] The purpose of the present invention is to solve the deficiencies of the prior art and provide a substituted phenolic hydroxyphenyl pyrrolopyrimidine compound and a preparation method and application thereof, specifically adopting the following technical solutions:

[0008] A substituted phenolic hydroxyphenyl pyrrolopyrimidine compound, the structural formula of which is shown in Formula I:

[0009] Wherein NR2R3 is one of a 3-9 membered saturated heterocyclic amino group and a dialkylamino group; the heterocyclic amino group contains at least one N atom and an O atom as ring atoms, and the heterocyclic amino group is connected to the rest of the molecule through the amino portion; the dialkylamino group is one of a dimethylamino group, a diethylamino group and a dipropylamino group; and n is any integer from 0 to 4.

[0010] The inventors of the present invention have found through extensive research that the above-mentioned substituted phenolic hydroxyphenyl pyrrolopyrimidine compound or a pharmaceutically acceptable salt thereof has the effect of highly efficient and selectively inhibiting the deubiquitinating enzyme USP51, can be used in the preparation and treatment of cancer prevention drugs, and can be used as an active ingredient in a pharmaceutical composition for treating cancer. The pharmaceutical composition contains one or more pharmaceutically acceptable excipients, and the dosage form of the above-mentioned pharmaceutical composition is any pharmaceutically acceptable dosage form, and can also be used in deubiquitinating enzyme USP51 inhibitors.

[0011] The above cancers include: gynecological cancers, such as ovarian cancer, cervical cancer, vaginal cancer, pudendal cancer, uterine / endometrial cancer, gestational trophoblastic tumor, fallopian tube cancer, uterine sarcoma; endocrine cancers, such as adrenal cortical cancer, pituitary cancer, pancreatic cancer, thyroid cancer, parathyroid cancer, thymic cancer, multiple endocrine neoplasia; bone cancers, such as osteosarcoma, Ewing's sarcoma, chondrosarcoma, etc.; lung cancers, such as small cell lung cancer, non-small cell lung cancer; brain and CN S tumors, such as neuroblastoma, acoustic neuroma, glioma and other brain tumors, spinal cord tumors, breast cancer, colorectal cancer, advanced colorectal adenocarcinoma; gastrointestinal cancers, such as liver cancer, extrahepatic bile duct cancer, gastrointestinal carcinoid tumors, gallbladder cancer, stomach cancer, esophageal cancer, small intestine cancer; genitourinary cancers, such as penile cancer, testicular cancer, prostate cancer; head and neck tumors, such as nasal cancer, paranasal sinus cancer, nasopharyngeal cancer, oral cancer, lip cancer, salivary gland cancer, laryngeal cancer, lower limb cancer, etc. Pharyngeal cancer, pharyngeal cancer; blood cancers, such as acute myeloid leukemia, acute lymphocytic leukemia, childhood leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia; bone marrow cancer blood diseases, such as myelodysplastic syndrome, myeloproliferative disorders, Fanconi anemia, aplastic anemia, essential macroglobulinemia; lymphoma, such as Hodgkin's disease, non-Hodgkin's disease The invention also includes the following cancers: retinoblastoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, AIDS-related lymphoma; eye cancers, including retinoblastoma and uveal melanoma; skin cancers, such as melanoma, non-melanoma skin cancer, and Merkel cell carcinoma; soft tissue sarcomas, such as Kaposi's sarcoma, childhood soft tissue sarcoma, and adult soft tissue sarcoma; urinary system cancers, such as renal cell carcinoma, Wilms' tumor, bladder cancer, urethral cancer, and metastatic cell carcinoma. Preferably, the invention is used for breast cancer, ovarian cancer, lymphoma, lung cancer, colorectal cancer, prostate cancer, bladder cancer, liver cancer, palate cancer, neuroblastoma, leukemia, or other cancers associated with the deubiquitinating enzyme USP51.

[0012] As a further preferred embodiment, the substituted phenolic hydroxyphenyl pyrrolopyrimidine compound is selected from any one of the following compounds 1-8:

[0013] As a further preferred embodiment, the structure of the substituted phenolic hydroxyphenyl pyrrolopyrimidine compound is as follows:

[0014] Compounds 1-8 of the present invention all showed excellent inhibitory activity against USP51, far exceeding the positive controls DHI and EPI, and compound 5 was more active than other analogs. The cardiotoxicity IC 50 The C maxand AUC, the oral half-life reaches 5.03h, and the oral bioavailability is 41.3%, which has high bioavailability.

[0015] The present invention also provides a method for preparing the above-mentioned substituted phenolic hydroxyphenyl pyrrolopyrimidine compound selected from the following compounds or pharmaceutically acceptable salts thereof, and the preparation route is as follows:

[0016] First, pyrrolopyrimidine A1 and 4-iodoanisole A2 undergo aromatic CN coupling reaction under the action of cuprous iodide to obtain intermediate A. Then, 4-alkynylaniline B1 and 4-nitrile iodobenzene B2 undergo Sonogaoka coupling reaction to obtain a large planar structure B3, which is then coupled with intermediate A to obtain intermediate B. B undergoes substitution reaction with different amino halides under the action of cesium carbonate and potassium iodide to obtain a series of target molecules.

[0017] The present invention also provides a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, wherein the excipients include at least one of carbohydrates, polymers, lipids or minerals.

[0018] The beneficial effects of the present invention are as follows: the preparation process of the present invention is simple and easy, and the prepared quinazoline compound or its pharmaceutically acceptable salt has the effect of effectively inhibiting the deubiquitinating enzyme USP51, has high selectivity, good safety, high solubility and high bioavailability, and provides new perspectives and ideas for broadening the understanding of the USP family, studying the relevant mechanism of the deubiquitinating enzyme USP51 participating in protein deubiquitination, and developing new anti-tumor small molecule drugs. DETAILED DESCRIPTION

[0019] The following will provide a clear and complete description of the concept, specific structure and technical effects of the present invention in conjunction with the embodiments and drawings to fully understand the purpose, scheme and effects of the present invention.

[0020] Example 1

[0021] Substituted phenolic hydroxyphenyl pyrrolopyrimidine compounds

[0022] Preparation of compound 1:

[0023] The structure of compound 1 is as follows:

[0024] The preparation process is as follows:

[0025] Step 1: Preparation of compound A:

[0026] The structure of compound A is as follows:

[0027] Compound A1 (300 mg, 1.03 mmol) was dissolved in 1,4-dioxane (5 mL), followed by the addition of compound A2 (285 mg, 0.49 mmol), cuprous iodide (18 mg, 0.08 mmol), trans-1,2-cyclohexanediamine (120 mg, 0.70 mmol), and potassium phosphate (500 mg, 3.01 mmol). The mixture was heated to 110°C in an oil bath and refluxed for 3 hours. The mixture was then filtered through celite and the liquid was concentrated using a rotary evaporator. The crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1 to 3:1) to afford compound 1 (white solid, 303 mg, yield: 70%).

[0028] The NMR test results of compound A are:

[0029] 1 H NMR (400MHz, DMSO-d6) δ9.82(d,J=2.5Hz,1H),9.02(d,J=2.5Hz,1H),7.90(t,J=3.0Hz,1H),7.51(dd,J=8.9,2.5Hz,2H),6.95(dd,J=8.9,2.5Hz, 2H),6.86(t,J=3.0Hz,1H). 13 C NMR(100MHz,Chloroform-d)δ157.33,153.18,152.41,151.45,132.06,128.29,126.23,118.74,116.27,101.41.HRMS(ESI):m / z calcd for C 33 H 33 N6O3 + [M+H] + :246.0429;found 246.0429.

[0030] The chemical formula of compound A1 in the above steps is as follows:

[0031] The chemical formula of compound A2 in the above steps is as follows:

[0032] Step 2: Preparation of compound B3

[0033] The structure of compound B3 is as follows:

[0034] Under argon, compound B1 (p-alkynylaniline, 100 mg, 0.785 mmol) was dissolved in tetrahydrofuran (5 mL), and compound B2 (4-cyanoiodobenzene, 170 mg, 0.776 mmol), cuprous iodide (14.9 mg, 0.0785 mmol), triethylamine (0.313 mL), and bistriphenylphosphine palladium dichloride (55.8 mg, 0.0785 mmol) were added. After refluxing overnight, the liquid in the vial was concentrated using a rotary evaporator, the reaction solution was washed with saturated NaCl solution, and extracted with ethyl acetate (3 × 100 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 7:1) to obtain compound B3 (white solid, 112 mg, yield: 66%).

[0035] The NMR test results of compound B3 are:

[0036] 1 H NMR(400MHz,Chloroform-d)δ8.30-8.13(m,1H),7.82(dd,J=7.6,1.8Hz,1H),7 .78-7.64(m,2H),7.17(dt,J=6.7,3.2Hz,1H),6.85-6.64(m,3H),3.87(s,2H).

[0037] The chemical formula of compound B1 in the above steps is as follows:

[0038] The chemical formula of compound B2 in the above steps is as follows:

[0039] Step 3: Preparation of compound B:

[0040] The structure of compound B is as follows:

[0041] Dissolve compound A (130 mg, 0.41 mmol) in 1,4-dioxane (4 mL), add compound B3 (130 mg, 0.62 mmol), palladium acetate (6 mg, 0.02 mmol), 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (35 mg, 0.02 mmol), and cesium carbonate (260 mg, 0.73 mmol). Place in an oil bath, heat to 110°C, reflux for 8 hours, filter through celite, and concentrate the contents on a rotary evaporator to obtain a crude product, which is used directly in the next step.

[0042] Step 4: Preparation of compound 1:

[0043] Compound A (60 mg, 0.14 mmol), potassium iodide (5.25 mg, 0.035 mmol), and cesium carbonate (114 mg, 0.35 mmol) were dissolved in acetonitrile (1 mL), and N,N-dimethylaminoethyl bromide hydrobromide (65 mg, 0.28 mmol) was then added. After refluxing overnight, the reaction was quenched by adding water. After the acetonitrile was dried, water (10 mL) and ethyl acetate (3×10 mL) were added for extraction. The organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 18:1) to obtain compound 1 (white solid, 53 mg, yield: 77%).

[0044] The NMR test results of compound 1 are:

[0045] 1 H NMR(400MHz,Chloroform-d)δ8.74(s,1H),7.74(d,J=8.4Hz,2H),7.65(dd,J=9.3,2.4Hz,2H),7.63-7.54(m,4H),7.48(d,J=8.4Hz,2H), 7.43(s,1H),7.24(d,J=3.7Hz,1H),7.13-7.06(m,2H),6.58(d,J=3.7Hz,1H),4.19(t,J=5.6Hz,2H),2.85(t,J=5.6Hz,2H),2.43(s,6H). 13 C NMR(100MHz,Chloroform-d)δ157. 5,155.5,151.5,151.0,141.3,132.7,132.0,131.9,130.9,128.8,126.6,125.0,118.7, 117.8,115.1,114.4,113.9,110.9,101.4,94.8,87.0,66.2,58.2,45.9.HRMS(ESI):m / z calcd for C 31 H 27 N6O + [M+H] + :499.2241; found 499.2244.

[0046] The chemical formula of N,N-dimethylaminoethyl bromide hydrobromide in the above steps is as follows:

[0047] Example 2

[0048] Preparation of compound 2:

[0049] The structure of compound 2 is as follows:

[0050] The preparation process is as follows:

[0051] Compound 2 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromoethyl)morpholine hydrobromide and keeping other conditions unchanged.

[0052] The NMR test results of compound 2 are:

[0053] 1 HNMR(400MHz,Chloroform-d)δ8.73(s,1H),7.76-7.72(m,2H),7.67-7.64(m,2H),7.63-7.57(m,4H),7.50-7.43(m,3H),7.24(d,J=3.7Hz, 1H),7.12-7.04(m,2H),6.58(d,J=3.7Hz,1H),4.21(t,J=5.7Hz,2H),3.81-3.72(m,4H),2.87(t,J=5.7Hz,2H),2.63(dd,J=5.7,3.8Hz,4H). 13 C NMR(100MHz,Chloroform-d)δ157.5,155.5,151.5,151.0,141.3,132.7,132.0,131.8,130.9,128.8,126.6, 125.1,118.7,117.8,115.2,114.4,113.9,110.9,101.4,94.7,87.0,66.9,66.2,57.7,54.2.HRMS(ESI):m / z calcd for C 33 H 29 N6O2 + [M+H] + :541.2347; found 541.2349.

[0054] The chemical formula of 4-(2-bromoethyl)morpholine hydrobromide in the above steps is as follows:

[0055] Example 3

[0056] Preparation of compound 3:

[0057] The structure of compound 3 is as follows:

[0058] The preparation process is as follows:

[0059] Compound 3 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromoethyl)piperazine hydrobromide while keeping other conditions unchanged.

[0060] The NMR test results of compound 3 are:

[0061] 1 H NMR(400MHz,Chloroform-d)δ8.74(s,1H),7.74(d,J=8.4Hz,2H),7.68-7.56(m,6H),7.48(t,J=7.4Hz,3H),7.24(d,J=3.7Hz ,1H),7.11-7.03(m,2H),6.58(d,J=3.7Hz,1H),4.20(t,J=5.7Hz,2H),2.90(t,J=5.7Hz,2H),2.82-2.54(m,8H),2.38(s,3H). 13 C NMR (101MHz, CDCl3) δ157.4,155.5,151.5,151.0,141.3,132.7,132.0,131.9,130.9,128.8,126.6,125.0, 118.7,117.8,115.1,114.4,113.9,110.9,101.4,94.8,87.0,66.3,57.1,54.9,53.1,45.7.HRMS(ESI):m / z calcd for C 34 H 32 N7O + [M+H] + :554.2663; found 554.2665.

[0062] The chemical formula of 4-(2-bromoethyl)piperazine hydrobromide in the above steps is as follows:

[0063] Example 4

[0064] Preparation of compound 4:

[0065] The structure of compound 4 is as follows:

[0066] The preparation process is as follows:

[0067] Compound 4 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromoethyl)pyrrole hydrobromide and keeping other conditions unchanged.

[0068] The NMR test results of compound 4 are:

[0069] 1 HNMR(400MHz,Chloroform-d)δ8.73(d,J=2.4Hz,1H),7.74(dd,J=8.7,2.4Hz,2H),7.67-7.58(m,6H),7.47(dd,J=8.7,2.4Hz,2H),7.36(s,1H) ,7.24(s,1H),7.11-7.06(m,2H),6.57(t,J=3.1Hz,1H),4.23(t,J=4.8H z,2H),3.01(t,J=4.8Hz,2H),2.73(d,J=5.9Hz,4H),1.89-1.85(m,4H). 13 C NMR(100MHz,Chloroform-d)δ157.5,151.0,141.3,132.7,132.0,131.9,130.8,128.8,126.6,125 .1,118.7,117.8,115.2,113.9,112.8,110.9,101.4,87.0,67.2,55.0,54.8,23.5.HRMS(ESI):m / z calcd for C 33 H 29 N6O + [M+H] + :525.2397; found 525.2399.

[0070] The chemical formula of 4-(2-bromoethyl)tetrahydropyrrole hydrobromide in the above steps is as follows:

[0071] Example 5

[0072] Preparation of compound 5:

[0073] The structure of compound 5 is as follows:

[0074] The preparation process is as follows:

[0075] Compound 5 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromoethyl)pyrrole hydrobromide and keeping other conditions unchanged.

[0076] The NMR test results of compound 5 are:

[0077] 1HNMR(400MHz,Chloroform-d)δ8.74(s,1H),7.75(d,J=8.4Hz,2H),7.69-7.58(m,4H),7.58(d,J=8.2Hz,2H),7.48(d,J=8.6Hz,3H),7.24(d, J=3.7Hz,1H),7.06(d,J=8.8Hz,2H),6.58(d,J=3.7Hz,1H),4.12(t,J=6.2Hz,2H),2.69(t,J=7.4Hz,2H),2.42(s,6H),2.12(p,J=6.6Hz,2H). 13 C NMR(100MHz,Chloroform-d)δ157.6,155.5,151.5,151.0,141.4,132.7,132.0,131.8,130.8,128.8,126.6, 125.0,118.7,117.8,115.0,114.3,113.9,110.9,101.4,94.8,87.0,66.3,56.3,45.1,27.0.HRMS(ESI):m / z calcd for C 32 H 29 N6O + [M+H] + :513.2397; found 513.2399.

[0078] The chemical formula of 4-(2-bromoethyl)tetrahydropyrrole hydrobromide in the above steps is as follows:

[0079] Example 6

[0080] Preparation of compound 6:

[0081] The structure of compound 6 is as follows:

[0082] The preparation process is as follows:

[0083] Compound 6 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromopropyl)morpholine hydrobromide and keeping other conditions unchanged.

[0084] The NMR test results of compound 6 are:

[0085] 1HNMR(400MHz,Chloroform-d)δ8.63(s,1H),7.64-7.54(m,4H),7.50(d,J=7.9Hz,4H),7.34(dd,J=8.5,2.8Hz,2H),7.16(d,J=3.7Hz,1H),6. 83(dd,J=8.7,2.9Hz,2H),6.49(d,J=3.7Hz,1H),4.07(d,J=7.7Hz,2H),3.68(d,J=4.5Hz,4H),2.42(d,J=16.4Hz,6H),1.94(t,J=7.8Hz,2H). 13 C NMR(100MHz,Chloroform-d)δ157.9,154.5,151.9,150.6,146.1,132.5, 132.0,132.0,130.6,128.5,126.1,125.9,124.7,118.6,118.0,115.9, 113.1,111.2,101.1,87.5,66.7,56.4,53.5,49.0,24.7.HRMS(ESI):m / z calcd for C 34 H 31 N6O2 + [M+H] + :555.2503; found 555.2505.

[0086] The chemical formula of 4-(2-bromopropyl)morpholine hydrobromide in the above steps is as follows:

[0087] Example 7

[0088] Preparation of compound 7:

[0089] The structure of compound 7 is as follows:

[0090] The preparation process is as follows:

[0091] Compound 7 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromopropyl)piperazine hydrobromide and keeping other conditions unchanged.

[0092] The NMR test results of compound 7 are:

[0093] 1HNMR(400MHz,Chloroform-d)δ8.74(s,1H),7.74(d,J=8.4Hz,2H),7.66-7.60(m,4H),7.58(d,J=8.4Hz,2H),7.47(d,J=8.4Hz,2H),7.39(s,1 H),7.24(d,J=3.7Hz,1H),7.09-7.03(m,2H),6.58(d,J=3.7Hz,1H),4.10(t,J=6.3Hz,2H),2.76-2.52(m,8H),2.33(s,3H),2.06-2.02(m,2H). 13 C NMR(100MHz,Chloroform-d)δ157.8,155.5,151.5,151.0,141.3,132.7,132.0,131.8,130.6,128.8,126.7,125.0 ,118.7,117.8,115.1,114.3,113.9,110.9,101.3,94.8,86.9,66.6,55.1,55.0,53.0,45.9,26.7.HRMS(ESI):m / z calcd for C 34 H 32 N7O + [M+H] + :568.2819; found 568.2820.

[0094] The chemical formula of 4-(2-bromopropyl)piperazine hydrobromide in the above steps is as follows:

[0095] Example 8

[0096] Preparation of compound 8:

[0097] The structure of compound 8 is as follows:

[0098] The preparation process is as follows:

[0099] Compound 8 was obtained by replacing N,N-dimethylaminoethyl bromide hydrobromide in Example 1 with 4-(2-bromopropyl)pyrrolidine hydrobromide and keeping other conditions unchanged.

[0100] The NMR test results of compound 8 are:

[0101] 1H NMR(400MHz,DMSO-d6)δ9.91(s,1H),8.86(s,1H),7.99-7.93(m,2H),7.91- 7.85(m,2H),7.82-7.76(m,2H),7.73-7.68(m,2H),7.64(d,J=3.7Hz,1H),7 .55-7.49(m,2H),7.24-7.16(m,2H),6.70(d,J=3.7Hz,1H),4.19(t,J=6.1H z,2H),3.39-3.23(m,6H),2.21(dt,J=13.2,6.0Hz,2H),1.98-1.89(m,4H). 13 C N R(100MHz,DMSO-d6)δ157.2,156.0,151.7,151.2,142.9,133.0,132.8,132.3,131.1,128.3,127.4,125.2, 119.0,118.2,115.5,113.7,113.0,110.8,101.9,95.3,87.4,65.8,53.4,51.8,25.9,23.2.HRMS(ESI):m / z calcd for C 34 H 31 N6O + [M+H] + :539.2554; found 539.2557.

[0102] The chemical formula of 4-(2-bromopropyl)tetrahydropyrrole hydrobromide in the above steps is as follows:

[0103] Example 9

[0104] Kinase activity screening

[0105] The USP in vitro kinase activity test was performed using the Ub-AMC (C-terminal-7-amido-labeled ubiquitin protein-4-methylcoumarin labeling) method to detect the direct interaction ability of the above-mentioned drug small molecules with protein kinases. These substrates are effectively cleaved or hydrolyzed by various deubiquitinating enzymes to release highly fluorescent parts. The fluorescent substrate AMC does not emit fluorescence when it binds to the ubiquitin chain. When USP cuts the fluorescent substrate AMC from the ubiquitin chain, AMC emits fluorescence, and the degree of inhibition of USP is analyzed by detecting the fluorescence intensity. At the same time, the compounds dihydromyricetin (DIH) and epigallocatechin (EPI) were selected as positive controls. The fluorescent substrate AMC and each drug molecule were added to the buffer respectively, and then the USP51 protein was added. The samples were centrifuged and mixed at 4°C and 12000 rpm, and the fluorescence intensity was detected on the machine. In order to more intuitively compare the differences in the enzyme activity of the compounds, the IC 50 Divided into four categories: 100nM <IC 50 <1μM(A), 10nM <IC50<100nM(B),1nM<IC 50 <10nM(C). The test results are shown in the table below: The specific test results are shown below:

[0106] As can be seen from the results in the above figure, compounds 1-8 all showed excellent inhibitory activity against USP51 that far exceeded the positive controls DHI and EPI, and compound 5 was more active than other analogs and is expected to be developed into a potential small molecule inhibitor of USP51.

[0107] Example 10

[0108] Selectivity evaluation of compound 5

[0109] The selectivity of the preferred compound 5 was further evaluated by enzyme activity analysis against 207 deubiquitinating enzyme targets, kinases, and proteases. The evaluation results showed that compound 5 had a strong inhibitory effect on USP51 with an IC50 of <10nM. It did not show significant selectivity for other DUBs and other targets, including USP1, USP5, OTUB1, USP7, USP9X, USP24, USP14, and USP15 (IC50 >1μM). These results indicate that compound 5 is a selective inhibitor of USP51.

[0110] Example 11

[0111] Safety evaluation of compound 5

[0112] The preferred compound 5 was evaluated for hERG cardiotoxicity. HEK293 cells stably transfected and expressing human myocardial HERG ion channels were used. The cultured cells were placed under an inverted microscope, and the recording electrodes were contacted to the cell surface by a micromanipulator. Membrane capacitance compensation and series resistance compensation were then performed to smooth the current line for subsequent testing. An 8-channel perfusion drug delivery system was controlled by a magnetic valve, and drug delivery was performed through the drug delivery electrode. The prepared compound 5 mother solution was diluted to 30μM, 10μM, 3μM, 1μM, and 0.3μM in proportion and added to the perfusion drug delivery system. The flow rate was controlled by gravity to continuously perfuse the cells. The drug delivery electrode was connected and adjusted to the upper left of the cell. After the cell current was recorded, it was perfused with the control group (not containing compound 5). After the current stabilized, it was replaced with compound 2 perfusion to observe its effect. According to Clampfit software analysis, the cardiotoxic IC50 of compound 5 was 12.23μM, showing a high safety.

[0113] Example 11

[0114] Oral bioavailability of compound 5

[0115] The preferred compound 5 was evaluated for bioavailability in mice. After fasting overnight, three mice were gavaged (50 mg / kg) and three mice were administered with tail vein administration (10 mg / kg). Subsequently, 0.1-0.2 mL of whole blood was collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h, respectively, and placed in a pre-heparinized sodium tube. The blood was gently flicked several times to fully mix with the sodium heparin and then centrifuged (4 ° C, 3000 rpm, 12 min) to obtain plasma. 50 μL of plasma sample was taken, 50 μL of diluent (50% methanol / water) and 250 μL of methanol precipitant were added, vortexed and centrifuged (4 ° C, 12000 rpm, 12 min), and the supernatant was sealed and sent for LC-MS / MS detection. The parameters were analyzed by WinNonlin software. Combined with the results in the table below, it shows that compound 5 has a high C max and AUC, the oral half-life reaches 5.03h, and the oral bioavailability is 41.3%, which has high bioavailability.

[0116] Although the present invention has been described in considerable detail and with particularity with respect to several described embodiments, it is not intended to be limited to any of these details or embodiments or any particular embodiment, but rather should be construed as providing a broad possible interpretation of these claims in view of the prior art by reference to the appended claims, thereby effectively encompassing the intended scope of the invention. In addition, the invention has been described above in terms of embodiments foreseen by the inventors for the purpose of providing a useful description, and those insubstantial modifications of the invention that are not currently foreseen may still represent equivalent modifications of the invention.

Claims

1. A substituted phenolic hydroxyphenyl pyrrolopyrimidine compound, characterized in that: Its structural formula is shown in Formula I: Wherein NR2R3 is one of a 3-9 membered saturated heterocyclic amino group and a dialkylamino group; the heterocyclic amino group contains at least one N atom and an O atom as ring atoms, and the heterocyclic amino group is connected to the rest of the molecule through the amino part; the dialkylamino group is one of a dimethylamino group, a diethylamino group and a dipropylamino group; and n is any integer from 0 to 4.

2. The substituted phenol hydroxyphenyl pyrrolopyrimidine compound according to claim 1, characterized in that: The structure of the substituted phenolic hydroxyphenyl pyrrolopyrimidine compound is any one of the following compounds 1-8:

3. A substituted phenol hydroxyphenyl pyrrolopyrimidine compound according to claim 2, characterized in that: The structure of the substituted phenol hydroxyphenyl pyrrolopyrimidine compound is as follows:

4. A substituted phenolic hydroxyphenyl pyrrolopyrimidine compound according to any one of claims 1 to 3, characterized in that: The preparation route is as follows:

5. Use of the substituted phenolic hydroxyphenyl pyrrolopyrimidine compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in the preparation of a drug for treating and / or preventing cancer.

6. The use according to claim 5, characterized in that: The cancer is breast cancer, ovarian cancer, lymphoma, lung cancer, colorectal cancer, prostate cancer, bladder cancer, liver cancer, palate cancer, neuroblastoma or leukemia.

7. Use of the quinazoline compound according to any one of claims 1 to 4 in the preparation of a deubiquitinating enzyme USP51 inhibitor.

8. A pharmaceutical composition, characterized in that The main active ingredient is the quinazoline compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3.

9. The pharmaceutical composition according to claim 8, characterized in that The pharmaceutical composition comprises one or more pharmaceutically acceptable excipients.

10. The pharmaceutical composition according to claim 9, characterized in that The excipient includes at least one of a carbohydrate, a polymer, a lipid or a mineral.

Citation Information

Patent Citations

  • Pyrimidine compound with effect of adhesion kinase inhibition and preparation method and application thereof

    CN103059030A

  • Deubiquitinase inhibitors and methods for use of the same

    CN105705504A

  • Pyrrolopyrimidine compound as well as preparation method, pharmaceutical composition and application thereof

    CN114957248A

  • Deubiquitinating enzyme USP25 and USP28 targeting inhibitor as well as preparation and application thereof

    CN115246832A

  • Substituted phenolic hydroxyl phenyl pyrrolopyrimidine compound as well as preparation method and application thereof

    CN116768902A

Cited By

  • Application of combination of USP51 inhibitor and PD-L1 / PD-1 monoclonal antibody drug in preparation of tumor immunotherapy drug

    CN120960439A